Satsuma Pharmaceuticals Inc - Ordinary Shares (STSA)
Symbol Info
Listed Symbol STSA
Name Satsuma Pharmaceuticals Inc - Ordinary Shares
Share Info
Annual Info
Latest Fiscal Dividend Per Share $-
Latest Fiscal Date 2018-12-31
Latest Fiscal Revenue $-
Latest Fiscal EPS $-1.86
Price Info
21 Day Moving Average $12.0602
21 Day EMA $13.773770
50 Day Moving Average $12.8287
50 Day EMA $15.924310
200 Day EMA $15.924310
200 Day Moving Average 12.828650
52 Week High $19.90
52 Week Low $8.61
52 Week Change $-68.761300
Alpha -0.257703
Beta -16.8104
Standard Deviation 0.166453
R2 1.000000
Periods 2
Share Information
10 Day Average Volume 60,320
20 Day Average Volume 67,765
30 Day Average Volume 107,190
50 Day Average Volume 64,314
Outstanding Shares 16,605,256
Float Shares 16,605,256
Percent Float 100.00%
Short Interest -
Short Percent Float -
Short Interest Ratio -
Short Date
Holders
Institutions 1
Institute Holdings Date 2019-09-30
Institute Bought Previous 3 Months -
Institute Holdings Percent -
Institute Sold Previous 3 Months -
Insider Holdings Date
Insider Bought Previous 3 Months -
Insider Holdings Percent -
Insider Sold Previous 3 Months -
Insiders Shares Owned -
Price Change
7 Day Price Change $0.6100006
7 Day Percent Change 6.27%
21 Day Price Change $-4.66
21 Day Percent Change -31.07%
30 Day Price Change $-5.1899996
30 Day Percent Change -33.42%
Month To Date Price Change $-4.67
Month To Date Percent -31.11%
90 Day Price Change $-22.759998
90 Day Percent Change -68.76%
Quarter To Date $-4.67
Quarter To Date Percent -31.11%
180 Day Price Change $-22.759998
180 Day Percent Change -68.76%
200 Day Price Change $-22.759998
200 Day Percent Change -68.76%
Year To Date $-22.759998
Year To Date Percent -68.76%
Profile
Description Satsuma Pharmaceuticals Inc is a clinical-stage biopharmaceutical company engaged in developing a novel therapeutic product for the treatment of migraine. Its product candidate, STS101, is a drug-device combination of a dry-powder formulation of dihydroergotamine mesylate, or DHE, which can be self-administered with a pre-filled, single-use, nasal delivery device.
Details
Issue Type CS
Market Cap $171,698,347
Sec Type
Auditor KPMG LLP
Total Shares Outstanding 16,605,256
CEO John A. Kollins
Employees 11
Last Audit UQ
Classification
CIK 0001692830
Industry Biotechnology
Sector Healthcare
NAICS Pharmaceutical Preparation Manufacturing(325412)
Info
Address 400 Oyster Point Boulevard
Suite 221
South San Francisco, CA 94080
Website https://www.satsumarx.com
Facisimile
Telephone +1 650 410-3200
Email tom@satsumarx.com
Key Ratios
Profitability
EBIT Margin -
EBITDA Margin -
Pre-Tax Profit Margin -
Profit Margin Cont -
Gross Margin -
Profit Margin TOT -
Income Statements
Revenue $-
Revenue Per Share $-
Revenue 3 Years $-
Revenue 5 Years $-
Valuation Measures
PE Ratio -
Enterprise Value $199,231,892
Price To Sales -
Price To Free Cash -12.6
PE High Last 5 Years -
Price To Book 3.6
Price To Cash Flow -
PE Low Last 5 Years -
Price To Tangible Book 3.6
Financial Strength
Total Debt To Equity 0.1
Int Coverage -38.3
Current Ratio 13.2
Leverage Ratio 1.7
Quick Ratio 12.3
Long Term Debt To Capital 0.07
Assets
Receivables Turnover -
Invoice Turnover -
Assets Turnover -
Management Effectiveness
Return Assets -21.52
Return On Equity -25
Return On Capital -15.97
Dividends
Dividend 3 Years $-
Dividend 5 Years $-
Ex Dividend Date
Dividend Rate $-
Dividend Yield -
Payment Type


Your Recent History
NASDAQ
STSA
Satsuma Ph..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.